Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
9 - Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 70 - 78Publisher: Cambridge University PressPrint publication year: 2016
References
Sackett, DL, Haynes, RB, Gibson, ES, Hackett, BC, Taylor, DW, Roberts, RS, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1(7918):1205–7.Google ScholarPubMed
Vermeire, E, Hearnshaw, H, Van Royen, P, Denekens, J. Patient adherence to treatment: three decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics. 2001;26(5):331–42.CrossRefGoogle ScholarPubMed
Ibrahim, AR, Eliasson, L, Apperley, JF, Milojkovic, D, Bua, M, Szydlo, R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733–6.CrossRefGoogle ScholarPubMed
Marin, D, Bazeos, A, Mahon, FX, Eliasson, L, Milojkovic, D, Bua, M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology. 2010;28(14):2381–8.CrossRefGoogle ScholarPubMed
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology. 2011;29(6):761–70.CrossRefGoogle ScholarPubMed
McMullin, MF, Bareford, D, Campbell, P, Green, AR, Harrison, C, Hunt, B, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology. 2005;130(2):174–95.CrossRefGoogle ScholarPubMed
Berk, PD, Goldberg, JD, Donovan, PB, Fruchtman, SM, Berlin, NI, Wasserman, LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology. 1986; 23(2): 132–43.Google ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine. 2013;368(1):22–33.CrossRefGoogle ScholarPubMed
McMullin, MF, Harrison, CN, Kiladjian, JJ. Treatment target in polycythemia vera. New England Journal of Medicine. 2013;368(16):1554–5.Google ScholarPubMed
Emanuel, RM, Dueck, AC, Geyer, HL, Kiladjian, JJ, Slot, S, Zweegman, S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology. 2012;30(33):4098–103.CrossRefGoogle ScholarPubMed
Harrison, CN, Bareford, D, Butt, N, Campbell, P, Conneally, E, Drummond, M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology. 2010;149(3):352–75.CrossRefGoogle ScholarPubMed
Barosi, G, Birgegard, G, Finazzi, G, Griesshammer, M, Harrison, C, Hasselbalch, H, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology. 2010;148(6):961–3.CrossRefGoogle ScholarPubMed
Barosi, G, Besses, C, Birgegard, G, Briere, J, Cervantes, F, Finazzi, G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21(2):277–80.Google ScholarPubMed
Hernandez-Boluda, JC, Alvarez-Larran, A, Gomez, M, Angona, A, Amat, P, Bellosillo, B, et al. Clinical evaluation of the European LeukemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. British Journal of Haematology. 2011;152(1):81–8.CrossRefGoogle Scholar
Harrison, CN. Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncology. 2005;1(5):609–18.CrossRefGoogle ScholarPubMed
Harrison, CN, Campbell, PJ, Buck, G, Wheatley, K, East, CL, Bareford, D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine. 2005;353(1):33–45.CrossRefGoogle ScholarPubMed
Gisslinger, H, Gotic, M, Holowiecki, J, Penka, M, Thiele, J, Kvasnicka, HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121(10):1720–8.CrossRefGoogle ScholarPubMed
Gowin, K, Thapaliya, P, Samuelson, J, Harrison, C, Radia, D, Andreasson, B, et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012;97(10):1570–3.CrossRefGoogle Scholar
Quintas-Cardama, A, Kantarjian, H, Manshouri, T, Luthra, R, Estrov, Z, Pierce, S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology. 2009;27(32):5418–24.CrossRefGoogle ScholarPubMed
Shariff, F, Harrison, C. Polycythemia vera: can we do better? Expert Opinion in Pharmacotherapy. 2013;14(6):687–9.CrossRefGoogle ScholarPubMed
Verstovsek, SK, Griesshammer, JJ, Masszi, M Durrant, T Passamonti, STS Harrison, F et al, CN. Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. Journal of Clinical Oncology. 2014 32:5s:(suppl; abstract 7026).CrossRefGoogle Scholar
Tefferi, A, Pardanani, A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic Proceedings 2011;86(12):1188–91.CrossRefGoogle ScholarPubMed
Andersen, CL, McMullin, MF, Ejerblad, E, Zweegman, S, Harrison, C, Fernandes, S, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology. 2013;162(4):498–508.CrossRefGoogle ScholarPubMed
Finazzi, G, Vannucchi, AM, Martinelli, V, Ruggeri, M, Nobile, F, Specchia, G, et al. A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. British Journal of Haematology. 2013;161(5):688–94.CrossRefGoogle ScholarPubMed
Baerlocher, GM, Leibundgut, EO, Ayran, C, Blaney, M, Burington, B, Morfeld, D, et al. Imetelstat rapidly induces and maintains substantial hematologic and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results. ASH Annual Meeting Abstracts. 2012;120(21):179.Google Scholar
Cervantes, F, Alvarez-Larran, A, Talarn, C, Gomez, M, Montserrat, E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. British Journal of Haematology. 2002;118(3):786–90.CrossRefGoogle Scholar
Passamonti, F, Rumi, E, Arcaini, L, Boveri, E, Elena, C, Pietra, D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–51.CrossRefGoogle ScholarPubMed
Campbell, PJ, Bareford, D, Erber, WN, Wilkins, BS, Wright, P, Buck, G, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. Journal of Clinical Oncology. 2009;27(18):2991–9.CrossRefGoogle ScholarPubMed
Silver, RT, Kiladjian, JJ, Hasselbalch, HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology. 2013;6(1):49–58.CrossRefGoogle ScholarPubMed
Finazzi, G, Caruso, V, Marchioli, R, Capnist, G, Chisesi, T, Finelli, C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664–70.CrossRefGoogle ScholarPubMed
Kiladjian, JJ, Chevret, S, Dosquet, C, Chomienne, C, Rain, JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. Journal of Clinical Oncology. 2011;29(29):3907–13.CrossRefGoogle ScholarPubMed
Schmitt, A, Drouin, A, Masse, JM, Guichard, J, Shagraoui, H, Cramer, EM. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leukemia and Lymphoma. 2002;43(4):719–24.CrossRefGoogle ScholarPubMed
Thiele, J, Kvasnicka, HM, Vardiman, JW, Orazi, A, Franco, V, Gisslinger, H, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. Journal of Clinical Oncology. 2009;27(34):e220–1; author reply e2–3.CrossRefGoogle ScholarPubMed
Thiele, J, Kvasnicka, HM, Zankovich, R, Diehl, V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica. 2000;85(11):1126–34.Google ScholarPubMed
Swerdlow, SH, Campo, E, Harris, NL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2008, pp. 67–86.Google Scholar
Wilkins, BS, Erber, WN, Bareford, D, Buck, G, Wheatley, K, East, CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60–70.CrossRefGoogle ScholarPubMed
Buhr, T, Hebeda, K, Kaloutsi, V, Porwit, A, Van der Walt, J, Kreipe, H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360–5.CrossRefGoogle Scholar
Mesa, RA, Verstovsek, S, Cervantes, F, Barosi, G, Reilly, JT, Dupriez, B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia Research. 2007;31(6):737–40.CrossRefGoogle Scholar
Barosi, G, Mesa, RA, Thiele, J, Cervantes, F, Campbell, PJ, Verstovsek, S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437–8.CrossRefGoogle Scholar
Bjorkholm, M, Derolf, AR, Hultcrantz, M, Kristinsson, SY, Ekstrand, C, Goldin, LR, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. Journal of Clinical Oncology. 2011;29(17):2410–5.CrossRefGoogle ScholarPubMed
Sterkers, Y, Preudhomme, C, Lai, JL, Demory, JL, Caulier, MT, Wattel, E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91(2):616–22.CrossRefGoogle ScholarPubMed
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology. 2011;29(6):761–70.CrossRefGoogle ScholarPubMed
Finazzi, G, Ruggeri, M, Rodeghiero, F, Barbui, T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. British Journal of Haematology. 2000;110(3):577–83.CrossRefGoogle ScholarPubMed
Berneman, ZN, Anguille, S, Van Marck, V, Schroyens, WA, Van Tendeloo, VF. Induction of complete remission of acute myeloid leukemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. British Journal of Haematology. 2010;149(1):152–5.CrossRefGoogle Scholar
Mesa, RA, Li, CY, Ketterling, RP, Schroeder, GS, Knudson, RA, Tefferi, A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973–7.CrossRefGoogle ScholarPubMed
Tam, CS, Nussenzveig, RM, Popat, U, Bueso-Ramos, CE, Thomas, DA, Cortes, JA, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112(5):1628–37.CrossRefGoogle ScholarPubMed
Ellis, MH, Lavi, N, Vannucchi, A, Harrison, C. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thrombosis Research. 2014; 134(2):251–4.CrossRefGoogle ScholarPubMed